Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
- Metastatic Malignant Solid Neoplasm
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Unresectable Solid Neoplasm
Interventions
- OTHER: Laboratory Biomarker Analysis
- OTHER: Pharmacogenomic Study
- OTHER: Pharmacological Study
- DRUG: Topotecan Hydrochloride
- DRUG: Veliparib
Sponsor
National Cancer Institute (NCI)